Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exelixis : Announces Webcasts of Investor Conference Presentations in February

share with twitter share with LinkedIn share with facebook
share via e-mail
02/06/2020 | 04:12pm EDT

Presentations to be webcast on www.exelixis.com

Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will be presenting at the following investor conferences in February:

  • BIO CEO & Investor Conference: Exelixis is scheduled to present at 2:00 PM EST / 11:00 AM PST on Tuesday, February 11, 2020 in New York.
  • Guggenheim Healthcare Talks Oncology Day: Exelixis is scheduled to present at 9:00 AM EST / 6:00 AM PST on Thursday, February 13, 2020 in New York.

To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for 14 days.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a registered Japanese trademark.

© Business Wire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on EXELIXIS, INC.
03/25EXELIXIS : Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (c..
03/02EXELIXIS : Announces George A. Scangos, Ph.D. to Retire From Its Board of Direct..
02/26EXELIXIS : Announces Webcasts of Investor Conference Presentations in March
02/25EXELIXIS : 4Q Earnings Snapshot
02/25EXELIXIS, INC. : Results of Operations and Financial Condition, Financial Statem..
02/25EXELIXIS : Management's Discussion and Analysis of Financial Condition and Resul..
02/25EXELIXIS : Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal T..
02/25EXELIXIS : Announces Fourth Quarter and Full Year 2019 Financial Results and Pro..
02/21EXELIXIS, INC. : annual earnings release
02/20EXELIXIS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year..
More news
Financials (USD)
Sales 2020 878 M
EBIT 2020 160 M
Net income 2020 141 M
Finance 2020 1 459 M
Yield 2020 -
P/E ratio 2020 40,6x
P/E ratio 2021 19,7x
EV / Sales2020 4,33x
EV / Sales2021 3,14x
Capitalization 5 259 M
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 24,10  $
Last Close Price 17,20  $
Spread / Highest target 104%
Spread / Average Target 40,2%
Spread / Lowest Target 10,5%
EPS Revisions
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Chief Financial & Accounting Officer, Executive VP
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.0.85%5 427
WUXI APPTEC CO., LTD.-5.02%20 264
GENMAB A/S-9.38%12 999